Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 13/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11277818 | 0.75 | USP2 (0.44) | GRIA4GRIA2MEN1KMT2AUSP2 | |
| SCHEMBL8289485 | 0.70 | GRIA4 (1.00) | GRIA4GRIA2 | |
| SCHEMBL4376765 | 0.70 | GRIA4 (0.75) | GRIA4GRIA2 | |
| SCHEMBL26967870 | 0.68 | GRIA4 (0.43) | GRIA4GRIA2ALDH1A1MEN1KMT2A | |
| SCHEMBL4378867 | 0.64 | ALDH1A1 (0.52) | GRIA4GRIA2ALDH1A1KMT2AMAPK1 | |
| SCHEMBL13295987 | 0.63 | KDM4E (0.40) | GRIA4GRIA2ALDH1A1MEN1KMT2A | |
| SCHEMBL29267759 | 0.63 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL15996308 | 0.63 | GRIA4 (0.82) | GRIA4GRIA2 | |
| SCHEMBL4372775 | 0.62 | KMT2A (0.50) | GRIA4GRIA2ALDH1A1TSHRKMT2A | |
| SCHEMBL9097378 | 0.62 | MELK (0.41) | GRIA4ALDH1A1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1991545-A2 | ANTIBACTERIAL PYRROLOPYRIDINES, PYRROLOPYRIMIDINES, AND PYRROLOAZEPINES | AstraZeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007071965-A2 | ANTIBACTERIAL PYRROLOPYRIDINES, PYRROLOPYRIMIDINES, AND PYRROLOAZEPINES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | SDHA, QDPR, PNKP | GRIA4 577/4885GRIA2 1035/4885ALDH1A1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.